Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.
Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.